Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.

Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.

Abstract: An LCD device and a method of driving the same are provided. The LCD device includes a panel, one or more gate driver IC, a timing controller, and a source driver IC. The gate driver IC sequentially drives a plurality of gate lines formed in the panel. The timing controller controls the gate driver IC. The source driver IC simultaneously transfers image data from a first latch to a second latch according to a latch signal, converts the image data transferred from the second latch into data voltages, and outputs the data voltages to the panel at a falling time of a source output enable signal.

Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.

Abstract: The present invention relates to a method for synthesizing ramalin, and more particularly to a method for synthesizing ramalin, which comprises allowing 2-hydrazinylphenol to react with L-glutamic acid having a protected carboxyl group at C-1 and a protected amino group at C-2, and a method for preventing decomposition of the ramalin. According to the present invention, ramalin having excellent antioxidant and anti-inflammatory activities can be synthesized in high yield, and thus can be produced in large amounts. In addition, ramalin can be stably maintained for a long period of time, and thus can be easily used for industrial purposes.

Abstract: The present invention relates to the novel use (anti-inflammatory activity) of Ramalin isolated from the Antarctic lichen Ramalina terebrata, and more specifically to a pharmaceutical composition containing Ramalin as an active ingredient. Ramalin of the invention is a compound derived from natural material, has no toxicity or side effects, and inhibits the expression of inducible nitric oxide synthase (iNOS) in the transcription stage to significantly inhibit the production of nitric oxide (NO) that is a key mediator of inflammatory responses. In addition, it inhibits the activation of the inflammatory mediator NF-?B, inhibits p38 MAPK, ERK1/2 and JNK signaling pathways, and inhibits the expression of the LPS receptor TLR4, suggesting that Ramalin has an excellent anti-inflammatory effect. Thus, the composition containing Ramalin can be effectively used to fundamentally treat or prevent inflammatory diseases or immune diseases and to relieve or alleviate the symptoms of the diseases.

Abstract: A line-on-glass type liquid crystal display device, which includes a gate drive integrated circuit mounted on a liquid crystal display panel for supplying a gate signal to the liquid crystal display panel, and a data drive integrated circuit for supplying a data voltage to the liquid crystal display panel. Further, the data drive integrated circuit includes an output circuit having effective output channels to which the data voltage is supplied and dummy output channels to which at least any one of the data voltage and a common voltage is supplied. Also included is a channel selecting part for selectively supplying any one of the data voltage and the common voltage to at least anyone of the dummy output channels.

Abstract: A liquid crystal display device includes a common voltage switching device selectively supplying one of first and second common voltages, a thin film transistor connected to a gate line and a data line, a liquid crystal capacitor connected to the thin film transistor and the common voltage switching device.

Abstract: A driver for a display device includes: a timing controller for generating first and second signals; and a plurality of data drivers provided with a plurality of data drivers disposed on the left of the timing controller, a data driver disposed at the center thereof, and a plurality of data drivers disposed on the right thereof, wherein the plurality of data drivers disposed on the left are driven in response to the first signal, and the plurality of data drivers disposed on the right are driven in response to the second signal.

Abstract: An apparatus for testing a display device includes a display device to display test patterns, a graphic process unit to supply analog mode signals and digital mode signals to the display device, and a control unit to allow test patterns of an analog testing mode and test patterns of a digital testing mode to be sequentially displayed on the display device upon receiving a control signal from the graphic process unit, and to output a control signal to the display device to sequentially change display characteristics of an image according to an on-screen-display mode testing menus.

Abstract: A liquid crystal display device includes a common voltage switching device selectively supplying one of first and second common voltages, a thin film transistor connected to a gate line and a data line, a liquid crystal capacitor connected to the thin film transistor and the common voltage switching device.

Abstract: An apparatus for testing a display device includes a display device to display test patterns, a graphic process unit to supply analog mode signals and digital mode signals to the display device, and a control unit to allow test patterns of an analog testing mode and test patterns of a digital testing mode to be sequentially displayed on the display device upon receiving a control signal from the graphic process unit, and to output a control signal to the display device to sequentially change display characteristics of an image according to an on-screen-display mode testing menus.